|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
27
|
|
pubmed:dateCreated |
2005-9-19
|
|
pubmed:abstractText |
Although complete resection (R0) of liver metastases (LM) remains the treatment of choice for colorectal cancer (CRC) patients amenable to curative therapy, only approximately one third survive for 5 years. The objective of this phase II study was to evaluate the safety and efficacy of radioimmunotherapy (RAIT) after salvage resection of LM.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:BeckerHeinzH,
pubmed-author:BehrThomas MTM,
pubmed-author:GhadimiB MichaelBM,
pubmed-author:GoldenbergDavid MDM,
pubmed-author:HorakIvan DID,
pubmed-author:KovacsJacquelineJ,
pubmed-author:KulleBettinaB,
pubmed-author:LangerClausC,
pubmed-author:LierschTorstenT,
pubmed-author:MarkusPeterP,
pubmed-author:MellerJohannesJ,
pubmed-author:WegenerWilliam AWA
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
20
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6763-70
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16170184-Adenocarcinoma,
pubmed-meshheading:16170184-Adult,
pubmed-meshheading:16170184-Aged,
pubmed-meshheading:16170184-Biopsy, Needle,
pubmed-meshheading:16170184-Carcinoembryonic Antigen,
pubmed-meshheading:16170184-Colorectal Neoplasms,
pubmed-meshheading:16170184-Combined Modality Therapy,
pubmed-meshheading:16170184-Disease-Free Survival,
pubmed-meshheading:16170184-Dose-Response Relationship, Radiation,
pubmed-meshheading:16170184-Female,
pubmed-meshheading:16170184-Hepatectomy,
pubmed-meshheading:16170184-Humans,
pubmed-meshheading:16170184-Immunohistochemistry,
pubmed-meshheading:16170184-Iodine Radioisotopes,
pubmed-meshheading:16170184-Liver Neoplasms,
pubmed-meshheading:16170184-Male,
pubmed-meshheading:16170184-Middle Aged,
pubmed-meshheading:16170184-Neoplasm Staging,
pubmed-meshheading:16170184-Prognosis,
pubmed-meshheading:16170184-Radioimmunotherapy,
pubmed-meshheading:16170184-Risk Assessment,
pubmed-meshheading:16170184-Salvage Therapy,
pubmed-meshheading:16170184-Survival Analysis,
pubmed-meshheading:16170184-Time Factors,
pubmed-meshheading:16170184-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results.
|
|
pubmed:affiliation |
Department of General Surgery, University of Göttingen, Germany. tliersc@gwdg.de
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Clinical Trial, Phase II
|
